3 New Strong Buy Ratings from Top-Rated Analysts: 09/12/2025

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Why Ligand Pharmaceuticals (LGND) is less subject to biotech volatility 
• With a robust pipeline, Alnylam Pharmaceuticals (ALNY) has analysts taking note 
• Remember Zoom Communications (ZM)? Guess what, it’s making a comeback. Here’s why.

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Ligand Pharmaceuticals (NASDAQ: LGND) 

Ligand Pharmaceuticals isn’t your average biotech company. Instead of developing drugs and treatments in-house, the business generates income by acquiring royalty rights and licensing platforms. LGND benefits from a highly diversified portfolio of over 90 treatments — and company insiders seem quite convinced that the stock has room to grow.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $167.93 — get current quote > 

Max 1-year forecast: $206.00 

Why we’re watching:

• LGND is a consensus Strong Buy on Wall Street — the stock has 2 Strong Buy ratings and 3 Buy ratings. See the ratings  
• The average 12-month price forecast for Ligand Pharmaceuticals shares, currently pegged at $179.80, implies a 7.19% upside.
• Benchmark equity researcher Robert Wasserman (a top 19% rated analyst) recently maintained a Strong Buy rating on the stock and hiked his price target from $160 to $175.
• Wasserman contextualized their price target hike with "the recent successful $460M convertible bond offering adds ammunition to Ligand Pharmaceuticals' royalty monetization and project finance efforts."
• LGND ranks in the top 10% of the stocks that we track, giving it a Zen Rating of B, which has historically corresponded with an average annual return of 19.88%.
• Ligand Pharmaceuticals shares currently rank in the top 14% of equities with regard to Growth.
• However, Sentiment is the stock’s strongest suit, as it ranks in the top 11% in this category. A key contributing factor to such a high rating is the fact that 38.41% of the insider transactions involving LGND in the past 12 months have been stock purchases. (See all 7 Zen Component Grades here >)

2. Alnylam Pharmaceuticals (NASDAQ: ALNY) 

Founded way back in 2002, Alnylam Pharmaceuticals is a biotech business that focuses on leveraging RNA-based therapies to treat rare genetic diseases. The company has already brought numerous treatments to market — it also maintains a robust pipeline, and Wall Street is quite optimistic regarding ALNY’s future prospects.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $455.10 — get current quote > 

Max 1-year forecast: $583.00 

Why we’re watching:

• Alnylam Pharmaceuticals enjoys broad, strongly bullish coverage from Wall Street analysts. The stock currently has 12 Strong Buy ratings, 8 Buy ratings, and 2 Hold ratings. See the ratings   
• Citigroup researcher David Lebovitz (a top 16% rated analyst) recently maintained a Strong Buy rating on ALNY and increased his price target from $527 to a Street-high $583.
• Lebovitz's price target hike followed Alnylam Pharmaceuticals' announcement of Phase 2 KARDIA-3 data for zilebesiran in uncontrolled hypertension.
• Although a single injection resulted in statistically significant reductions of systolic blood pressure after three months and at six months, the analyst said that was not significant enough to meet the pre-specified criteria. 
• Nonetheless, zilebesiran offers an "intriguing" profile, Lebovitz noted.
• At present, ALNY ranks in the 89th percentile of the equities that we track, giving it a Zen Rating of B.
• Alnylam Pharmaceuticals shares have rallied by 94.14% since the start of the year. ALNY ranks in the top 12% of stocks when it comes to Momentum.
• Our Artificial Intelligence Component Grade rating is derived from the findings of a neural network trained on more than 20 years of market data. That neural network has identified Alnylam Pharmaceuticals as a likely outperfomer — in this category, the stock ranks in the top 10%.
• Lastly, we have Growth — and in terms of this Component Grade rating, ALNY ranks in the 97th percentile. (See all 7 Zen Component Grades here >)

3. Zoom Communications (NASDAQ: ZM) 

Let’s jump on a quick call, and we’ll explain why Zoom deserves a closer look. Just kidding — while you might think of Zoom as yesterday’s news in comparison to, say, Microsoft Teams, Google Meet, or Slack (and it probably brings up not-so-pleasant memories of a global pandemic), the business has made ample strides in growing enterprise revenue and reducing customer churn.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $83.62 — get current quote > 

Max 1-year forecast: $110.00 

Why we’re watching:

• Zoom is a consensus Buy as per Wall Street analysts. The stock currently has 2 Strong Buy ratings, 5 Buy ratings, 9 Hold ratings, and 1 Strong Sell rating. See the ratings  
• However, the average price target for the stock, currently set at $89.82, sets a more bullish note, as it implies a healthy 8.5% upside.
• Catharine Trebnick of Rosenblatt (a top 9% rated analyst) maintained a Strong Buy rating on ZM after the company reported its Q2 2026 earnings. Trebnick also increased her price target from $100 to a Street-high $110. 
• Trebnick summed up the print by saying that revenue growth was the strongest in eleven quarters and management raised its FY 2026 guidance.
• Looking ahead, Zoom now provides more transparency regarding growth, maintained its share repurchase program, and is opening up new avenues for monetizing AI, the analyst said.
• Zoom is the 3rd highest-rated stock in the App industry, which has an Industry rating of B.
• ZM ranks in the 98th percentile of the more than 4,600 stocks that we track, giving it a Zen Rating of A, which has historically corresponded to an average annual return of 32.52%.
• Zoom shares are currently trading at a price-to-earnings (P/E) ratio of 21.23x, and rank in the top 5% of equities in terms of Value.
• In addition, ZM ranks in the 96th percentile when it comes to both Sentiment and Financials. (See all 7 Zen Component Grades here >)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.